Wang J, Zhu W, Li X, Wu Y, Ma W, Wang Y
Front Pharmacol. 2025; 16:1500251.
PMID: 39981173
PMC: 11839622.
DOI: 10.3389/fphar.2025.1500251.
Mehinrad P, Abdelfattah A, Sadat S, Shafaati T, Elmenoufy A, Jay D
Drug Deliv Transl Res. 2025; .
PMID: 39878858
DOI: 10.1007/s13346-024-01782-9.
Tuscharoenporn T, Apaijai N, Charoenkwan K, Chattipakorn N, Chattipakorn S
Cancer Gene Ther. 2025; 32(2):149-164.
PMID: 39843770
DOI: 10.1038/s41417-025-00871-2.
Patel B, Patel S, Modi F, Patel A, Gelat B, Tanavde V
Sci Rep. 2024; 14(1):30672.
PMID: 39730440
PMC: 11680578.
DOI: 10.1038/s41598-024-74277-9.
Sokolova V, Gruber R, Pammer L, Kocher F, Klieser E, Amann A
Mol Biol Rep. 2024; 52(1):87.
PMID: 39729162
PMC: 11680630.
DOI: 10.1007/s11033-024-10169-5.
FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma.
Tang L, Chen J, Wu Z, Wang L, Lai Y, Chen Z
J Cancer. 2024; 15(20):6490-6504.
PMID: 39668821
PMC: 11632979.
DOI: 10.7150/jca.96877.
Characterization and Bioactive Metabolite Profiling of sp. Y009: A Mangrove-Derived with Anticancer and Antioxidant Potential.
Yu B, Zeng W, Zhou Y, Li N, Liang Z
Microorganisms. 2024; 12(11).
PMID: 39597689
PMC: 11596135.
DOI: 10.3390/microorganisms12112300.
Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma.
Zhang Y, Ojalill M, Boyer A, Chen X, Tahon E, Thivolle Lioux G
Cancer Res Commun. 2024; 4(12):3165-3179.
PMID: 39585085
PMC: 11659947.
DOI: 10.1158/2767-9764.CRC-24-0382.
Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer.
Fu Y, Lin H, Ou Y, Wu C, Fu H
BMC Cancer. 2024; 24(1):1377.
PMID: 39529011
PMC: 11552161.
DOI: 10.1186/s12885-024-13087-8.
STUB1 suppresses paclitaxel resistance in ovarian cancer through mediating HOXB3 ubiquitination to inhibit PARK7 expression.
Zhao L, Yang H, Wang Y, Yang S, Jiang Q, Tan J
Commun Biol. 2024; 7(1):1439.
PMID: 39501077
PMC: 11538469.
DOI: 10.1038/s42003-024-07127-z.
Advances in research on the relationship between the LMNA gene and human diseases (Review).
Zhao J, Zhang H, Pan C, He Q, Zheng K, Tang Y
Mol Med Rep. 2024; 30(6).
PMID: 39422026
PMC: 11529173.
DOI: 10.3892/mmr.2024.13358.
Aulosirazole Stimulates FOXO3a Nuclear Translocation to Regulate Apoptosis and Cell-Cycle Progression in High-Grade Serous Ovarian Cancer (HGSOC) Cells.
Khin M, Davis L, Lantvit D, Orjala J, Burdette J
Mol Pharmacol. 2024; 106(3):145-154.
PMID: 39079718
PMC: 11331498.
DOI: 10.1124/molpharm.124.000921.
Role of Cancer Side Population Stem Cells in Ovarian Cancer Angiogenesis.
Pan Y, Yang X, Chen M, Shi K, Lyu Y, Meeson A
Med Princ Pract. 2024; 33(5):403-413.
PMID: 39068919
PMC: 11460956.
DOI: 10.1159/000539642.
Enhancing ovarian cancer treatment with maleimide-modified Pt(IV) prodrug nanoparticles.
Bai Y, Wang Z, Liu D, Meng X, Wang H, Yu M
Mater Today Bio. 2024; 27:101131.
PMID: 39050986
PMC: 11267080.
DOI: 10.1016/j.mtbio.2024.101131.
Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma.
Iwanaga R, Yamamoto T, Gomez K, Nguyen L, Woodruff E, Post M
Cancer Res Commun. 2024; 4(8):1919-1932.
PMID: 38984891
PMC: 11298703.
DOI: 10.1158/2767-9764.CRC-24-0027.
Muscle weakness and mitochondrial stress occur before severe metastasis in a novel mouse model of ovarian cancer cachexia.
Delfinis L, Ogilvie L, Khajehzadehshoushtar S, Gandhi S, Garibotti M, Thuhan A
Mol Metab. 2024; 86:101976.
PMID: 38925248
PMC: 11278933.
DOI: 10.1016/j.molmet.2024.101976.
ANGPTL3 diminishes the resistance of ovarian cancer to paclitaxel by blocking the PI3K-AKT-mTOR signaling pathway.
Wu D, Liu J, Yang X, Wu Z, Wang T, Xiao M
Heliyon. 2024; 10(11):e31520.
PMID: 38828336
PMC: 11140616.
DOI: 10.1016/j.heliyon.2024.e31520.
Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.
Nunes M, Bartosch C, Abreu M, Richardson A, Almeida R, Ricardo S
Cells. 2024; 13(9.
PMID: 38727322
PMC: 11083313.
DOI: 10.3390/cells13090786.
Long noncoding RNA TUG1 promotes cisplatin resistance in ovarian cancer via upregulation of DNA polymerase eta.
Sonobe R, Yang P, Suzuki M, Shinjo K, Iijima K, Nishiyama N
Cancer Sci. 2024; 115(6):1910-1923.
PMID: 38558246
PMC: 11145130.
DOI: 10.1111/cas.16150.
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.
Tavares V, Marques I, de Melo I, Assis J, Pereira D, Medeiros R
Int J Mol Sci. 2024; 25(3).
PMID: 38339123
PMC: 10856127.
DOI: 10.3390/ijms25031845.